In this webinar, seasoned ADC experts together with multiple myeloma clinical investigator Shambavi Richard will discuss how the Heidelberg’s innovative ADCs pipeline has the potential to transform the lives of patients with hard to treat cancers. With its track record of ADC development and innovation, Heidelberg Pharma is developing multiple candidates with distinct modes of action (MOA) targeting malignant hematologic and solid tumors:

• +90% of cancer deaths are attributed to drug resistance, one of the biggest challenges in oncology - Heidelberg Pharma’s unique payload, Amanitin offers the potential to transform drug resistance
• Derived from the Amanita phalloides mushroom, Amanitin offers a novel MOA which is cell-cycle independent, effectively targeting both dividing and dormant tumor cells, debulking the tumor and killing cancer stem cells, that are known to be key drivers of tumor relapse and metastasis
• Its lead clinical candidate - HDP-101, an Anti-BCMA antibody Amanitin drug conjugate, is demonstrating efficacy data from its Phase I/IIa clinical trials targeting relapsed or refractory multiple myeloma
• Heidelberg Pharma is also leveraging its technology across of a variety of malignant hematologic and solid tumors, and expanding its pipeline to include as payload exatecan, a TOPO1 inhibitorJoin us to learn more about the latest preclinical and clinical data on these next generation ADCs.